Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: Evidence from in vitro studies on human prostatic and pancreatic cancers

Endocrinology

Volumn 141, Issue 6, 2000, Pages 2120-2128

  Rekasi, Zoltan ^a,b,c   Varga, Jozsef L ^a,b   Schally, Andrew V ^a,b   Halmos, Gabor ^a,b   Armatis, Patricia ^a   Groot, Kate ^a   Czompoly, Tamas ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH HORMONE RELEASING FACTOR; PROSTATE SPECIFIC ANTIGEN; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0034455291     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.141.6.7511     Document Type: Article

References (55)

1. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasm potentially dependent on IGF-I
2. Growth hormone-releasing hormone: Clinical perspectives
3. Hypothalamic and other peptide hormones
4. Antagonistic analogs of growth hormone-releasing hormone (GH-RH): Endocrine and oncological studies
5. Antagonistic analogs of growth hormone-releasing hormone (GH-RH): New potential antitumor agents
6. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone
7. Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH)
8. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities
9. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone
10. Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone
11. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone
12. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of CAKI-I renal adenocarcinoma
13. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumors
14. Growth hormone-releasing hormone: An autocrine growth factor for small cell lung carcinoma
15. Growth hormone-releasing antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors
16. Antagonists of growth hormone-releasing hormone (GH-RH) decrease IGF-II production of HT-29 human colon cancer cells and inhibit tumour growth
17. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice
18. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro
19. Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone
20. In vitro identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging
21. Peptides and growth factors in non-small cell lung cancer
22. 2 receptor
23. Retinoic acid down-regulates the expression of the vasoactive intestinal polypeptide receptor type-1 in human breast carcinoma cell lines
24. Human adrenocortical NCI-H295 cells express VIP receptors. Steroidogenic effect of vasoactive intestinal peptide (VIP)
25. Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo
26. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth
27. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist
28. Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone
29. 2 receptors
30. Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro
31. 1 receptor
32. The human prostate gland: A histochemical and immunohistochemical study of neuropeptides, serotonin, dopamine β-hydroxylase and acetylcholinesterase in autonomic nerves and ganglia
33. Neuroendocrine peptides in the prostate
34. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate
35. Vasoactive intestinal peptide: Biologic role in health and disease
36. Modulation of cyclic AMP and inositol phosphate production in rat prostatic cultures by VIP/PACAP, ATP and carbachol. Role in prostatic proliferation
37. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells
38. Vasoactive intestinal peptide stimulates prostate-specific antigen secretion by LNCaP prostate cancer cells
39. Prostate-specific antigen: Its usefulness in clinical medicine
40. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
41. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells
42. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay
43. The dispersed cell superfusion system
44. A method for evaluation of activity of antagonistic analogs of growth hormone-releasing hormone in a superfusion system
45. Receptors for vasoactive intestinal peptide in rat anterior pituitary glands: Localization of binding to lactotropes
46. Use of radioreceptor assay and cell superfusion system for in vitro screening of analogs of growth hormone-releasing hormone
47. Ligand: A versatile computerized approach for characterization of ligand binding systems
48. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC
49. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: Quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction
50. 1 subtype is predominant in rat prostate membranes
51. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in rat pineal gland
52. Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone
53. Identification of human growth hormone-releasing hormone receptor splicing variants
54. Identification of alternatively spliced messenger ribonucleic acid encoding truncated growth hormone-releasing hormone receptor in human pituitary adenomas
55. Binding sites for growth hormone releasing factor on rat anterior pituitary cells